NEW YORK, NY / ACCESSWIRE / October 4, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
GoHealth, Inc. (NASDAQ:GOCO)
The GoHealth lawsuit is on behalf of all purchasers of GoHealth Class A common stock pursuant and/or traceable to the registration statement issued in connection with GoHealth's July 2020 initial public offering.
Lead Plaintiff Deadline: November 20, 2020
The GOCO lawsuit alleges GoHealth, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (ii) GoHealth suffered from a higher risk of customer churn as a result of its unique business model and limited carrier base; (iii) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company's concentrated carrier business model, and GoHealth's efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (iv) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (v) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the initial public offering.
Learn about your recoverable losses in GOCO: http://www.kleinstocklaw.com/pslra-1/gohealth-inc-loss-submission-form?id=9787&from=1
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020
The complaint alleges that throughout the class period BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BMRN: http://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?id=9787&from=1
Peabody Energy Corporation (NYSE:BTU)
Class Period: April 3, 2017 - October 28, 2019
Lead Plaintiff Deadline: November 27, 2020
The BTU lawsuit alleges that Peabody Energy Corporation made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (b) the Company failed to follow its own safety procedures; (c) as a result, the North Goonyella mine was at a heightened risk of shutdown; (d) the Company's low-cost plan to restart operations at the mine posed unreasonable safety and environmental risks; (e) The Australian body responsible for ensuring acceptable health and safety standards, the Queensland Mines Inspectorate, would likely mandate a safer, cost-prohibitive approach; and (f) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production.
Learn about your recoverable losses in BTU: http://www.kleinstocklaw.com/pslra-1/peabody-energy-corporation-loss-submission-form?id=9787&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm